Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age

Previously, the Vi-typhoid conjugate vaccine (Vi-TT) was found to be highly efficacious in Nepalese children under 16 years of age. We assessed the immunogenicity of Vi-TT at 9 and 12 months of age and response to a booster dose at 15 months of age. Infants were recruited at Patan Hospital, Kathmand...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2024-03, Vol.42 (8), p.2018-2025
Main Authors: Bijukchhe, Sanjeev M., Gurung, Meeru, Pokhrel, Bhishma, Shakya, Mila, Pant, Dikshya, Maskey, Pratistha, Maskey, Himang, Dhakal, Babita, Rajkarkinar, Shristy, Bista, Sabitri, Voysey, Merryn, Mujadidi, Yama F., Kim, Young Chan, Atherton, Rachel, Jones, Elizabeth, Mclean, Florence, Shrestha, Sonu, Hill, Matilda, Nyland, Katherine Theiss, Kelly, Sarah, O'reilly, Peter, Sah, Ganesh Prasad, Basnyat, Buddha, Pollard, Andrew J., Shrestha, Shrijana
Format: Article
Language:English
Subjects:
Age
Antibodies
Antibodies, Bacterial
Binding sites
Booster
Child
Children
Clinical trials
Conjugate
Conjugates
COVID-19
Enzyme-linked immunosorbent assay
Fever
Guardians
Humans
Immune response
Immunity
Immunization
Immunogenicity
Immunogenicity, Vaccine
Immunoglobulin G
Infant
Informed consent
Nepal
Nepal - epidemiology
Pandemics
Seroconversion
Tetanus
Typhoid
Typhoid Fever - prevention & control
Typhoid-Paratyphoid Vaccines
Vaccine
Vaccines
Vaccines, Conjugate
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previously, the Vi-typhoid conjugate vaccine (Vi-TT) was found to be highly efficacious in Nepalese children under 16 years of age. We assessed the immunogenicity of Vi-TT at 9 and 12 months of age and response to a booster dose at 15 months of age. Infants were recruited at Patan Hospital, Kathmandu and received an initial dose of Vi-TT at 9 or 12 months of age with a booster dose at 15 months of age. Blood was taken at four timepoints, and antibody titres were measured using a commercial ELISA kit. The primary study outcome was seroconversion (4-fold rise in antibody titre) of IgG one month after both the doses. Fifty children were recruited to each study group.Some visits were disrupted by the COVID19 pandemic and occurred out of protocol windows.Both the study groups attained 100 % IgG seroconversion after the initial dose. IgG seroconversion in the 9-month group was significantly higher than in the 12-month group (68.42 % vs 25.8 %, p 
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2024.02.010